第61回日本神経学会学術大会

セッション情報

印刷

シンポジウム

[S-48] シンポジウム48
アルツハイマー病基礎研究最前線

2020年9月2日(水) 09:00 〜 10:30 第12会場 (岡山国際交流センター 8F イベントホール)

座長：樋口 真人（量子科学技術研究開発機構 放射線医学総合研究所）,岩田 淳（地方独立行政法人東京都健康長寿医療センター脳神経内科）

[S-48-1] 治療薬の非臨床開発を通じた認知症分子病態の解明

○樋口 真人 (量子科学技術研究開発機構 放射線医学総合研究所 脳機能イメージング研究部)

In recent years, many clinical trials for Alzheimer's disease (AD) have ended in disappointment. Now it's time to rethink strategy to defeat AD. In this symposium, researchers at the vanguard of AD basic research will introduce their recent remarkable work, including elucidation of AD pathomechanisms, generation of AD animal models, and establishing new concepts of therapies and biomarkers utilizing cutting-edge technologies. We believe that talk in this session will provide neurologists important insights to gain a better understanding of AD.

[S-48-2] アルツハイマー病における病原性タンパク質の伝播と治療介入

○岩坪 威 (東京大学医学系 神経病理学)

In recent years, many clinical trials for Alzheimer's disease (AD) have ended in disappointment. Now it's time to rethink strategy to defeat AD. In this symposium, researchers at the vanguard of AD basic research will introduce their recent remarkable work, including elucidation of AD pathomechanisms, generation of AD animal models, and establishing new concepts of therapies and biomarkers utilizing cutting-edge technologies. We believe that talk in this session will provide neurologists important insights to gain a better understanding of AD.

[S-48-3] アルツハイマー病モデル動物作製　マウスから非ヒト霊長類へ

○笹栗 弘貴1,2 (1.理化学研究所脳神経科学研究センター 神経老化制御研究チーム, 2.東京医科歯科大学大学院 脳神経病態学)

In recent years, many clinical trials for Alzheimer's disease (AD) have ended in disappointment. Now it's time to rethink strategy to defeat AD. In this symposium, researchers at the vanguard of AD basic research will introduce their recent remarkable work, including elucidation of AD pathomechanisms, generation of AD animal models, and establishing new concepts of therapies and biomarkers utilizing cutting-edge technologies. We believe that talk in this session will provide neurologists important insights to gain a better understanding of AD.

[S-48-4] アルツハイマー病におけるゲノムDNAの統合性

○間野 達雄 (東京大学病院 脳神経内科)

In recent years, many clinical trials for Alzheimer's disease (AD) have ended in disappointment. Now it's time to rethink strategy to defeat AD. In this symposium, researchers at the vanguard of AD basic research will introduce their recent remarkable work, including elucidation of AD pathomechanisms, generation of AD animal models, and establishing new concepts of therapies and biomarkers utilizing cutting-edge technologies. We believe that talk in this session will provide neurologists important insights to gain a better understanding of AD.

[S-48-5] タウ伝播を標的としたアルツハイマー病治療法の開発

○武田 朱公 (大阪大学大学院医学系研究科臨床遺伝子治療学)

In recent years, many clinical trials for Alzheimer's disease (AD) have ended in disappointment. Now it's time to rethink strategy to defeat AD. In this symposium, researchers at the vanguard of AD basic research will introduce their recent remarkable work, including elucidation of AD pathomechanisms, generation of AD animal models, and establishing new concepts of therapies and biomarkers utilizing cutting-edge technologies. We believe that talk in this session will provide neurologists important insights to gain a better understanding of AD.